#42

The timing of the IPO doesn’t look good for BioAge
https://securities.stanford.edu/filings-case.html?id=108512

1 Like
#43

BioAge completed its initial public offering on September 27, 2024, selling 12.65 million shares at $18 per share. However, less than three months later, on December 6, 2024, BioAge announced that it would discontinue the ongoing STRIDES Phase 2 study of its investigational drug candidate azelaprag after liver transaminitis was observed in some subjects receiving azelapgrag. In response to the news, BioAge’s stock price declined from $20.09 per share on December 6, 2024 to $4.65 per share on December 7, 2024.

How did that happen?

#44

This happens more than you would think.

4 Likes
#45

Were any puts available for BioAge stock? Biotech stocks in general have high volatility potential, so if you like the thrill of high risk high reward :rofl:…

1 Like
#46

No, that part I know, I was just wondering how, what went wrong.

#47

It was strange… the drug had already been through phase 1 and phase 2 studies in Japan for Asthma when they purchased it (in-licensed it), so it should have been fine. Perhaps the new patient population was older than the Japanese cohort? Hard to know without a detailed look but sad news whatever the case:

liver transaminitis was the problem:

Transaminitis: What it is, Symptoms, Causes & Treatment.

3 Likes